Literature DB >> 16949376

Pathophysiology of contrast-induced nephropathy.

James Tumlin1, Fulvio Stacul, Andy Adam, Christoph R Becker, Charles Davidson, Norbert Lameire, Peter A McCullough.   

Abstract

Contrast-induced nephropathy (CIN) is the third leading cause of acute kidney injury in hospitalized patients and is associated with significant patient morbidity. The pathogenesis of CIN is complex and not fully understood, but iodinated contrast agents induce intense and prolonged vasoconstriction at the corticomedullary junction of the kidney. Moreover, high-osmolar dyes directly impair the autoregulatory capacity of the kidney through a loss of nitric oxide production. These effects, coupled with direct tubular toxicity of contrast media, lead to overt acute tubular necrosis and the syndrome of CIN.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16949376     DOI: 10.1016/j.amjcard.2006.01.020

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  80 in total

Review 1.  Contrast-induced acute kidney injury: the at-risk patient and protective measures.

Authors:  Jeremiah R Brown; Craig A Thompson
Journal:  Curr Cardiol Rep       Date:  2010-09       Impact factor: 2.931

2.  Interventional cardiology: Hand me your radial artery to protect your kidney.

Authors:  Giora Weisz; Martin B Leon
Journal:  Nat Rev Cardiol       Date:  2010-12       Impact factor: 32.419

Review 3.  Acute Kidney Injury following Cardiac Surgery: A Clinical Model.

Authors:  Frederic T Billings
Journal:  Nephron       Date:  2019-07-03       Impact factor: 2.847

Review 4.  High-resolution CT vascular imaging using blood pool contrast agents.

Authors:  Ananth V Annapragada; Eric Hoffman; Abhay Divekar; Efstathios Karathanasis; Ketan B Ghaghada
Journal:  Methodist Debakey Cardiovasc J       Date:  2012-01

5.  Contemporary incidence, predictors, and outcomes of acute kidney injury in patients undergoing percutaneous coronary interventions: insights from the NCDR Cath-PCI registry.

Authors:  Thomas T Tsai; Uptal D Patel; Tara I Chang; Kevin F Kennedy; Frederick A Masoudi; Michael E Matheny; Mikhail Kosiborod; Amit P Amin; John C Messenger; John S Rumsfeld; John A Spertus
Journal:  JACC Cardiovasc Interv       Date:  2014-01       Impact factor: 11.195

6.  Cerebral computed tomography angiography using a 70 kVp protocol: improved vascular enhancement with a reduced volume of contrast medium and radiation dose.

Authors:  Eun-Suk Cho; Tae-Sub Chung; Sung Jun Ahn; KyoungHoon Chong; Jang Hun Baek; Sang Hyun Suh
Journal:  Eur Radiol       Date:  2014-12-16       Impact factor: 5.315

7.  Acute kidney injury after out-of-hospital cardiac arrest: risk factors and prognosis in a large cohort.

Authors:  Guillaume Geri; Lucie Guillemet; Florence Dumas; Julien Charpentier; Marion Antona; Virginie Lemiale; Wulfran Bougouin; Lionel Lamhaut; Jean-Paul Mira; Christophe Vinsonneau; Alain Cariou
Journal:  Intensive Care Med       Date:  2015-05-14       Impact factor: 17.440

Review 8.  The hemodynamic and nonhemodynamic crosstalk in cardiorenal syndrome type 1.

Authors:  Grazia Maria Virzì; Anna Clementi; Alessandra Brocca; Massimo de Cal; Giorgio Vescovo; Antonio Granata; Claudio Ronco
Journal:  Cardiorenal Med       Date:  2014-05-14       Impact factor: 2.041

9.  Iodinated contrast media cause direct tubular cell damage, leading to oxidative stress, low nitric oxide, and impairment of tubuloglomerular feedback.

Authors:  Zhi Zhao Liu; Kristin Schmerbach; Yuan Lu; Andrea Perlewitz; Tatiana Nikitina; Kathleen Cantow; Erdmann Seeliger; Pontus B Persson; Andreas Patzak; Ruisheng Liu; Mauricio M Sendeski
Journal:  Am J Physiol Renal Physiol       Date:  2014-01-15

10.  Brain natriuretic peptide for prevention of contrast-inducednephropathy: a meta-analysis of randomized controlled trials.

Authors:  Xue-Biao Wei; Lei Jiang; Xin-Rong Liu; Dan-Qing Yu; Ning Tan; Ji-Yan Chen; Ying-Ling Zhou; Peng-Cheng He; Yuan-Hui Liu
Journal:  Eur J Clin Pharmacol       Date:  2016-10-01       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.